OncoMatch

OncoMatch/Clinical Trials/NCT07280013

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Is NCT07280013 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Elranatamab and Cemsidomide for multiple myeloma (mm).

Phase 1RecruitingC4 Therapeutics, Inc.NCT07280013Data as of May 2026

Treatment: Cemsidomide · Elranatamab — The main purpose of the study is to understand the safety and tolerability of cemsidomide when given along with elranatamab in subjects with relapsed or refractory multiple myeloma. The first part of the study will evaluate different dose levels of cemsidomide in combination with elranatamab in a limited number of subjects. Approximately 3 different dose levels of cemsidomide in combination with elranatamab may be explored. Once a dose level is determined safe, additional subjects may be enrolled through expansion of the dose level. This expansion will provide further exploration of the safety and evaluation of preliminary antimyeloma activity. Cemsidomide will be taken orally each cycle for 14 days on/14 days off (1 cycle=28 days). Elranatamab will be administered by subcutaneous injection twice a month. Dexamethasone will be administered weekly until a confirmed response but no longer than 4 cycles.

Check if I qualify

Extracted eligibility criteria

Cancer type

Multiple Myeloma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Max 4 prior lines
Min 2 prior lines

Must have received: immunomodulatory drug (IKZF 1/3 degrader)

at least 1 immunomodulatory drug (i.e., IKZF 1/3 degrader)

Cannot have received: BCMA-directed T-cell engager

Prior treatment with a BCMA-directed TCE

Cannot have received: BCMA-directed CAR-T cell therapy

Prior treatment with a BCMA-directed CAR-T therapy

Cannot have received: stem cell transplant

Exception: within 12 weeks prior to enrollment

Stem cell transplant within 12 weeks prior to enrollment

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Duke Cancer Center · Durham, North Carolina
  • Oregon Health & Science University · Portland, Oregon
  • Houston Methodist Hospital · Houston, Texas
  • MD Anderson Cancer Center · Houston, Texas
  • Huntsman Cancer Institute, University of Utah · Salt Lake City, Utah

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify